Table 3.
Baseline characteristics of two patient groups with left ventricular systolic dysfunction 6 months after discharge post ST-segment elevation myocardial infarction based on the need for hospitalization for heart failure in long-term follow-up.
| Variable | With HF Hospitalization in Long-Term Follow-Up (n = 16) | Without HF Hospitalization in Long-Term Follow-Up (n = 19) | p-Value |
|---|---|---|---|
| Age (years) | 57.0 (53.0–64.0) | 61.0 (50.0–67.0) | 0.935 |
| Gender (male:female) n (%) | 11:5 (68.8:31.3) | 15:4 (78.9:21.1) | 0.492 |
| Anterior location of STEMI n (%) | 15 (93.8) | 16 (84.2) | 0.365 |
| HF prior to STEMI (I/II NYHA) n (%) | 1 (6.3) | 2 (10.5) | 0.082 |
| HF at discharge for STEMI (≥II NYHA) n (%) | 5 (31.3) | 5 (26.3) | 0.418 |
| Body mass index (kg/m²) | 29.4 (27.3–30.7) | 27.4 (24.5–29.4) | 0.088 |
| Hypertension n (%) | 8 (50) | 11 (57.9) | 0.640 |
| Diabetes mellitus n (%) | 5 (31.3) | 5 (26.3) | 0.748 |
| Creatinine at admission (µmol/L) | 88.4 (79.6–98.1) | 88.4 (70.7–91.3) | 0.656 |
| Glucose at admission (mmol/L) | 7.75 (6.75–10.8) | 9.00 (7.94–10.7) | 0.125 |
| Leukocyte count on admission (10³/µL) | 12.6 (10.9–13.6) | 11.7 (9.50–12.5) | 0.441 |
| Leukocyte count 24 h after admission (10³/µL) | 12.4 (9.38–14.0) | 12.3 (8.74–13.4) | 0.461 |
| LDL cholesterol at admission (mmol/L) | 3.63 (3.26–5.01) | 3.72 (3.44–4.22) | 0.781 |
| CK-MBmax (U/L) | 203.5 (157.5–240.0) | 148.0 (119.0–206.0) | 0.172 |
| TnImax (ng/mL) | >50.0 (>50.0–>50.0) | >50.0 (>50.0–>50.0) | 0.350 |
| CRP at admission (mg/L) | 2.59 (1.42–4.24) | 1.6 (0.82–1.77) | 0.014 |
| CRP 24 h after admission (mg/L) | 29.5 (17.8–43.8) | 20.11 (6.21–26.7) | 0.056 |
| CRP at discharge (mg/L) | 21.9 (12.36–43.7) | 15.4 (7.95–24.66) | 0.161 |
| CRP 1 month after discharge (mg/L) | 2.57 (1.69–3.48) | 1.54 (0.65–2.72) | 0.052 |
| BNP at admission (pg/mL) | 108.9 (23.2–269.7) | 61.9 (31.0–132.4) | 0.502 |
| BNP at discharge (pg/mL) | 384.8 (198.8–756.0) | 336.5 (233.0–717.5) | 0.781 |
| LAD/non-LAD n (%) | 15 (93.8) | 17 (89.8) | 0.649 |
| TIMI 3 flow pre-PCI n (%) | 2 (12.5) | 1 (5.3) | 0.733 |
| TIMI 3 flow post-PCI n (%) | 14 (87.5) | 15 (78.9) | 0.978 |
| TMPG 3 post-PCI n (%) | 7 (43.8) | 8 (42.1) | 0.615 |
| Multivessel coronary disease n (%) | 11 (68.8) | 11 (57.9) | 0.507 |
| Abciximab use n (%) | 7 (43.8) | 8 (42.1) | 0.922 |
| LVEF at discharge for STEMI (%) | 36.0 (32.8–39.7) | 36.8 (35.0–40.4) | 0.301 |
| WMSI at discharge for STEMI (pts) | 1.88 (1.81–1.97) | 1.81 (1.75–1.88) | 0.095 |
| LVEF 6 months after discharge for STEMI (%) | 35.8 (31.3–37.0) | 36.9 (35.0–39.2) | 0.056 |
| WMSI 6 months after discharge for STEMI (pts) | 1.88 (1.84–1.97) | 1.75 (1.63–1.88) | 0.029 |
Data represent median values with corresponding interquartile range (in parentheses). Abbreviations: BNP—B-type natriuretic peptide; CK-MBmax—maximal activity of isoenzyme MB of creatine kinase; CRP—high-sensitivity C-reactive protein; HF—heart failure; HDL cholesterol—high-density lipoprotein cholesterol; LAD—infarct-related left descending artery; LDL cholesterol—low-density lipoprotein cholesterol; LVEF—left ventricular ejection fraction; LVSD—left ventricular systolic dysfunction; NYHA—New York Heart Association; PCI—primary percutaneous coronary intervention; STEMI—ST-segment elevation myocardial infarction; TIMI—Thrombolysis in Myocardial Infarction score; TMPG—TIMI Myocardial Perfusion Grade; TnImax—maximal concentration of troponin I; WMSI—wall motion score index.